Many provincial governments in Canada have placed strict restrictions on access to DAA treatments limiting eligibility for public reimbursement of treatment costs to people whose virus has progressed to cause significant fibrosis and damage to their liver.
These restrictive criteria are not based in best practice or medical evidence and are in opposition to recommendations made by expert bodies in the field of Hepatology including the Canadian Association for the Study of the Liver and the American Association for the Study of Liver Diseases.
Requiring the virus to progress to advanced liver disease before treatment denies early access to a cure and raises the risk of future medical complications caused by HCV .
Get the Position Paper
The AHC released a position paper on this subject in October 2015.